Transient hypercalcemia followed by hypocalcemia in a preterm infant after maternal magnesium sulfate therapy.
bone change
hypercalcemia
hypocalcemia
magnesium sulfate
Journal
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
ISSN: 0918-5739
Titre abrégé: Clin Pediatr Endocrinol
Pays: Japan
ID NLM: 9433330
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
10
2021
accepted:
11
12
2021
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
ppublish
Résumé
Maternal use of magnesium sulfate has been associated with neonatal hypocalcemia and bone changes. We report the case of a preterm male infant who presented hypercalcemia before developing hypocalcemia after maternal magnesium sulfate therapy. Magnesium sulfate was used for premature rupture of membranes for 32 days, and the patient was delivered at 33 weeks gestation. The cord blood showed ionized calcium 1.54 mmol/L. His serum calcium and magnesium were 11.4 mg/dL and 3.5 mg/dL after birth and fell to 6.6 mg/dL and 2.7 mg/dL at 6 hours, respectively. The intact parathyroid hormone level was 18 pg/mL at 6 h. Radiography showed transverse radiolucent metaphyseal bands of the proximal humerus bone, suggesting disturbance in normal ossification. Transient hypercalcemia before the development of hypocalcemia after maternal magnesium sulfate therapy has not been previously reported. We speculate that maternal long-term magnesium sulfate therapy led to defective ossification and transient hypercalcemia in the offspring. Subsequent hypocalcemia was thought to be due to the inhibition of parathyroid hormone secretion by hypercalcemia and hypermagnesemia.
Identifiants
pubmed: 35431443
doi: 10.1297/cpe.2021-0061
pii: 2021-0061
pmc: PMC8981048
doi:
Types de publication
Case Reports
Langues
eng
Pagination
77-80Informations de copyright
2022©The Japanese Society for Pediatric Endocrinology.
Déclaration de conflit d'intérêts
The authors have declared that no conflict of interest exists.
Références
BJOG. 2020 Sep;127(10):1180-1188
pubmed: 32237069
AIMS Public Health. 2016 May 30;3(2):348-356
pubmed: 29546168
Gynecol Obstet Invest. 1997;44(2):82-8
pubmed: 9286718
N Engl J Med. 1984 May 10;310(19):1221-5
pubmed: 6709029
J Clin Med. 2021 Mar 29;10(7):
pubmed: 33805460
Pediatr Dermatol. 2019 Jan;36(1):24-30
pubmed: 30187956
Early Hum Dev. 2010 Mar;86(3):187-91
pubmed: 20226604
Acta Paediatr. 2001 Mar;90(3):278-81
pubmed: 11332167
Semin Fetal Neonatal Med. 2020 Feb;25(1):101076
pubmed: 31882392
J Pediatr. 1980 Feb;96(2):305-10
pubmed: 7351603
Cell Mol Biol (Noisy-le-grand). 2016 Dec 30;62(14):59-63
pubmed: 28145858
Pediatr Radiol. 2004 Aug;34(8):673-4
pubmed: 15221242